WHO recommends monoclonal antibody treatments for Ebola disease


The World Health Organization (WHO) has published its first guideline on the treatment of Ebola virus disease and has strongly recommended two monoclonal antibody treatments.

Ebola is a serious and deadly disease caused by the Ebola virus. Previous Ebola outbreaks and responses have shown that early diagnosis and treatment with optimized supportive care, such as fluid and electrolyte replenishment and treatment of symptoms, significantly improve survival. Following a systematic review and meta-analysis of randomized clinical trials of therapeutics for the disease, the WHO has now recommended monoclonal antibodies – mAb114 (Ansuvimab; Ebanga) and REGN-EB3 (Inmazeb).

Clinical trials were conducted during Ebola outbreaks, with the largest trial being conducted in the Democratic Republic of Congo, demonstrating that the highest level of scientific rigor can be applied even during Ebola outbreaks in challenging settings.

“These (guidance) will help reassure communities, health workers and patients that this life-threatening disease can be treated with effective medicines. From now on, people infected with the Ebola virus will have a better chance of recovering if they seek treatment as soon as possible. As with other infectious diseases, speed is key and people should not hesitate to see health workers as soon as possible to ensure they are receiving the best possible care,” said Dr Richard Kojan, co-chair of the expert group for the elaboration of the guidelines selected by the WHO. and President of ALIMA, the Alliance for International Medical Action.

Both recommended treatments have demonstrated clear benefits and can therefore be used for all patients confirmed positive for Ebola virus disease, including the elderly, pregnant and breastfeeding women, children and neonates born to affected mothers. of Ebola confirmed within the first seven days after birth, the Who said. Patients should receive the recommended neutralizing monoclonal antibodies as soon as possible after laboratory confirmation of the diagnosis.

There is also a recommendation on which therapies should not be used to treat patients: these include ZMapp and remdesivir. All of these recommendations apply only to Ebola virus disease caused by Ebola virus (EBOV; Zaire ebolavirus).

Although the WHO was able to make strong recommendations for the use of two therapeutics, it said further research and evaluation of clinical interventions is needed as many uncertainties remain.


Comments are closed.